Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

September 23, 2016September 23, 2016

Genentech’s Tecentriq Seen to Significantly Increase Survival in Patients with Specific Type of Lung Cancer

Lung Cancer, News

Genentech recently announced positive results for its cancer immunotherapy Tecentriq (atezolizumab) being tested in the Phase 3 clinical trial OAK (NCT02008227). Tecentriq is a monoclonal antibody designed to bind to an immune checkpoint protein ... Read more

June 30, 2016June 30, 2016

Stem Cell Therapy Improves Lives of COPD Patients, but It’s Not a Cure

COPD, News

A patient named Gary V. at the Lung Institute in Tampa, Florida, with chronic obstructive pulmonary disease (COPD), shared how his life improved since receiving stem cell therapy. When discussing the improvements that ... Read more

June 29, 2016June 29, 2016

Phase 1 Trial Data on RNA-based Therapy for CF to Be Presented at NACFC 2016

Cystic Fibrosis, News

ProQR Therapeutics recently announced that new data from an ongoing proof-of-concept clinical study, called PQ-010-002, evaluating the effect of an RNA-based therapy (QR-010) on cystic fibrosis patients, will be presented at the North American Cystic Fibrosis Conference ... Read more

June 22, 2016June 22, 2016

Riociguat is Safe and Effective Way of Treating CTEPH Treatment Over Long Term, Review Finds

News, Pulmonary Hypertension

Results from the ongoing Phase 3 study known as CHEST-2 support the long-term use of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH). The findings are detailed in the study, “Predictors ... Read more

June 20, 2016June 20, 2016

Genetic Mutations Linked to CF in Study, While Others Found to Be Benign

Cystic Fibrosis, News

A large screening of children in California helped to identify and distinguish a number of mutations likely to cause cystic fibrosis (CF) from mutations that are benign. The study, “Benign and Deleterious Cystic Fibrosis Transmembrane Conductance ... Read more

June 16, 2016June 16, 2016

Promising Results of Kalydeco and Orkambi for Cystic Fibrosis Presented at European CF Conference

News

Vertex Pharmaceuticals scientists presented positive results from clinical studies evaluating Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor) at the 39th European Cystic Fibrosis Society (ECFS) Conference June 8-11 in Basel, Switzerland. The presentations included real-world data from ... Read more

June 9, 2016June 9, 2016

Crucial Molecule May Lead to Novel Therapies for Pulmonary Arterial Hypertension

News, Pulmonary Hypertension

In a recent study published in the The Journal of Clinical Investigation, researchers reported to have identified a crucial factor for the development of pulmonary arterial hypertension (PAH). The discovery identified a ... Read more

May 17, 2016May 17, 2016

Newborn CF Screening Associated with Improved Growth at Puberty and Taller Adults, Study Reports

Cystic Fibrosis, News

Researchers at the University of Wisconsin-Madison reported that newborn screening for cystic fibrosis is associated with improved pubertal development, leading to taller adult height when compared to cystic fibrosis children ... Read more

May 13, 2016May 13, 2016

GlaxoSmithKline (GSK) to Present Studies on Respiratory Diseases Therapies at ATS 2016

Asthma, COPD, News

GlaxoSmithKline (GSK) recently announced that the company will present the most recent results obtained in a wide range of GSK studies, focused on their respiratory portfolio of approved medicines, at ... Read more

April 21, 2016April 21, 2016

Specific Non-small Cell Lung Cancer Patients Show Improvement in ARIAD’s Clinical Trial for Brigatinib

News

ARIAD Pharmaceuticals recently presented updated data from an ongoing Phase 1/2 trial testing brigatinib, an investigational tyrosine kinase inhibitor, in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) ... Read more